프릴릭시맙
Priliximab| 단클론 항체 | |
|---|---|
| 유형 | 전항체 |
| 출처 | 치메릭(쥐/인간) |
| 대상 | CD4 |
| 임상자료 | |
| ATC 코드 |
|
| 식별자 | |
| CAS 번호 | |
| 켐스파이더 |
|
  (이게 뭐야?) (iii) | |
프릴릭시맙(cMT 412)은 인간 쥐의 치메릭 반CD4 단클론 항체다.크론 병과[1] 다발성[2][3] 경화증 환자들을 대상으로 검사했지만 아직 미국 식품의약국(FDA) 허가를 받지 못했다.특허는 생명공학 회사 센토코르에 속한다.
참조
- ^ Stronkhorst A, Radema S, Yong S, Bijl H, ten Berge I, Tytgat G, van Deventer S (1997). "CD4 antibody treatment in patients with active Crohn's disease: a phase 1 dose finding study". Gut. 40 (3): 320–7. doi:10.1136/gut.40.3.320. PMC 1027080. PMID 9135519.
- ^ Llewellyn-Smith N, Lai M, Miller D, Rudge P, Thompson A, Cuzner M (1997). "Effects of anti-CD4 antibody treatment on lymphocyte subsets and stimulated tumor necrosis factor alpha production: a study of 29 multiple sclerosis patients entered into a clinical trial of cM-T412". Neurology. 48 (4): 810–6. doi:10.1212/wnl.48.4.810. PMID 9109860. S2CID 9938490.
- ^ van Oosten B, Lai M, Hodgkinson S, Barkhof F, Miller D, Moseley I, Thompson A, Rudge P, McDougall A, McLeod J, Adèr HJ, Polman C (1997). "Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial". Neurology. 49 (2): 351–7. doi:10.1212/wnl.49.2.351. PMID 9270561. S2CID 8294890.
